Prosecution Insights
Last updated: October 21, 2026

Frank Ziemer Holding AG

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Frank Ziemer Holding AG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, PURDY, KYLE A, and is categorized within a distinct art unit. PURDY, KYLE A is the busiest examiner for the portfolio, overseeing 1 pending office action.

The single pending office action and distinct art unit indicate a very specific and limited prosecution presence at this time. Because there is only 1 pending office action, PURDY, KYLE A is the sole examiner interacting with the company's biotechnology and pharmaceutical filings. This centralized structure means that the company's current success in this technology area depends on the review of this one individual. This focus allows the company to direct its attention toward a single critical patent matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PURDY, KYLE A 1 41.0% +35.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18611811 EYE COLORANT AND METHOD FOR MANUFACTURING A PATIENT INDIVIDUAL EYE COLORANT PURDY, KYLE A —

Top Art Units

Art UnitApps
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18611811 EYE COLORANT AND METHOD FOR MANUFACTURING A PATIENT INDIVIDUAL EYE COLORANT PURDY, KYLE A 1611 §102 Non-Final OA — Pending Mar 21, 2024

Managing Frank Ziemer Holding AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Frank Ziemer Holding AG have?

Frank Ziemer Holding AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Frank Ziemer Holding AG applications?

Kyle A Purdy has the most, with 1 of Frank Ziemer Holding AG's pending office actions.

What technology area are Frank Ziemer Holding AG's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month